Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
i see stem cells in news lately. scll? got anything on scll?
Stem cell treatment still a way off in U.S.
FDA says therapy doesn't work now, may be dangerous
By Christina E. Sanchez • THE TENNESSEAN • August 1, 2010
Stem cell treatments have been researched legally in the United States for decades, but they are still out of reach at home for Americans who seek alternative treatments to debilitating diseases.
http://www.tennessean.com/article/20100801/NEWS01/8010362
In other countries, stem cell transplants are used to treat conditions such as Parkinson's disease, multiple sclerosis, liver cirrhosis, stroke, glaucoma and spinal cord injuries.
But within the United States, stem cell treatments could be a decade or more from approval by the Food and Drug Administration. Doctors say the therapy doesn't work at this time and may even be dangerous.
"If the United States had a promising therapy that had been shown to be effective, it would be using it," said Dr. Mark Magnuson, director of the Vanderbilt Center for Stem Cell Biology. "It's a risky therapy, and not only will it do nothing, but it could do harm."
Related
MS patient goes to Mexico for stem cell transplant, chance to walk again
Dawn Gusty's stem cell transplant
What are stem cells?
What is multiple sclerosis?
Embryonic stem cells are the most controversial because the cells are taken from 4- or 5-day-old human embryos, a method that raises ethical questions. In March, President Barack Obama lifted an eight-year ban on federal funding for embryonic stem cell research.
Adults also have stem cells, which go around the body to replenish other dying cells and to take on specialized jobs, according to the National Institutes for Health.
In Dawn Gusty's case, they could repair the nerve endings that were destroyed by her multiple sclerosis.
"This is all over the scientific world," said Dr. Gustavo Andrade, who performed Gusty's therapy in Tijuana, Mexico. "There are all these things we don't understand yet. Will the cells attach to the inflammation, and for how long? It could be for a long time, it could be a few months, but each patient is different."
'Not the magic bullet'
No one tracks how many people travel outside the United States each year for stem cell transplants, but estimates are at least 800 people. Treatments can cost between $20,000 and $150,000.
This year, Stem Cells for Hope, the New York company that Gusty used, helped 27 patients who went through a review panel of doctors and researchers. They can't be older than 80 and must fit into a category of about eight diseases, said Peter Sidorenko, chief operating officer.
He said most people who seek out the company say, "My doctors said there was nothing they could do for me."
"This is not the magic bullet that is going to cure everything," said Sidorenko, who acknowledges there are companies that scam or lack expertise. "But we are helping people with degenerative diseases. We're just scratching the surface of what this type of medical procedure can achieve."
Magnuson said he doesn't dispute that stem cells hold promise for new therapies in the future — particularly embryonic stem cells, his area of expertise.
"We're 10 to 12 years into this, and that may seem like a lot of time, but what we do takes time," Magnuson said. "Any new stem cell therapy is going to be looked at by the FDA to make sure it doesn't cause more damage than good."
Contact Christina E. Sanchez
at 615-726-5961 or cesanchez@tennessean.com.
Keryx Biopharmaceuticals Receives Orphan Drug Designation for KRX-0401 (Perifosine) for the Treatment of Neuroblastoma
Keryx Biopharmaceuticals (MM) (NASDAQ:KERX)
Intraday Stock Chart
Today : Wednesday 14 July 2010
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that KRX-0401 (perifosine) has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of neuroblastoma, a cancer of the nervous system affecting mostly children and infants for which there are no FDA approved therapies.
Phase 1 data of perifosine in recurrent pediatric solid tumors, including neuroblastoma, was presented last month in the pediatric solid tumor poster discussion session held at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Investigators from the Memorial Sloan-Kettering Cancer Center concluded that perifosine was demonstrated to be safe and well tolerated in children with advanced solid tumors and that perifosine may have antitumor clinical activity as a single agent in neuroblastoma. Additionally, in a preclinical study recently published in the Journal of the National Cancer Institute, perifosine showed a statistically significant reduction in neuroblastoma cell survival, slowed or regressed tumor growth, and increased survival in mice bearing neuroblastoma tumors. A decreased level of activated Akt was also observed in perifosine-treated neuroblastoma cells and xenograft tumors.
Ron Bentsur, Chief Executive Officer of Keryx, commented, "The Orphan Drug designation is an important component of our development plan for perifosine in neuroblastoma, an indication where no FDA approved therapies currently exist." Mr. Bentsur continued, "We are currently exploring next steps for the development of perifosine in this indication which we hope, ultimately, could provide a new treatment option for children and infants suffering with neuroblastoma."
Perifosine is currently in Phase 3 clinical development for refractory advanced colorectal cancer and multiple myeloma, both of these Phase 3 programs being conducted under Special Protocol Assessment (SPA) agreements with the FDA with Fast Track designations obtained for both indications. Perifosine is also in Phase 1 and 2 clinical development for several other tumor types.
KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris, Inc. in the United States, Canada and Mexico.
About Orphan Drug Designation
Orphan drug designation is granted by the FDA Office of Orphan Drug Products to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. The designation provides the drug developer with a seven-year period of U.S. marketing exclusivity if the drug is the first of its type approved for the specified indication or if it demonstrates superior safety, efficacy, or a major contribution to patient care versus another drug of its type previously granted the designation for the same indication, as well as with tax credits for clinical research costs, the ability to apply for annual grant funding, clinical research trial design assistance and waiver of Prescription Drug User Fee Act (PDUFA) filing fees.
About Neuroblastoma
Tue 4:16PM EDT GERN
STEM
These Cold Stocks Are Heating Upat Motley Fool
I have 3 Children 2 from one and one from another.Head spinner for sure.You can find me here http://www.facebook.com/home.php?#!/profile.php?id=1316317029 Goodnight Mick !
I have plenty of kids ! Nite My Friend Morning comes early for me.
two ways of making breast milk. having babies or one that has cancer developes breat milk in women.
I knew thats why I drink it !LOL
Thanks Mick!
wow, me either. did ya see where breast milk can cure cancer?
Cant wait for all the Trials to end!
we haven't had much to chat about stem cell companies of late.
their research still goes on though.
Data on VIVUS' Qnexa to be Featured at World Congress Highlighting Metabolic Disease and Related Disorders
Date : 05/13/2010 @ 7:00AM
Source : PR Newswire
Stock : Vivus (MM) (VVUS)
Quote : 12.35 0.25 (2.07%) @ 7:22AM
Data on VIVUS' Qnexa to be Featured at World Congress Highlighting Metabolic Disease and Related Disorders
Data on VIVUS' Qnexa to be Featured at World Congress Highlighting Metabolic Disease and Related Disorders
PR Newswire
MOUNTAIN VIEW, Calif., May 13
MOUNTAIN VIEW, Calif., May 13 /PRNewswire-FirstCall/ --
VIVUS, Inc. (Nasdaq: VVUS) today announced that data on Qnexa®, an investigational drug candidate, will be presented at the 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) in Prague, Czech Republic. Timothy Garvey, MD, professor of medicine and chair of the department of nutrition sciences at the University of Alabama at Birmingham and a Qnexa investigator, will deliver an oral presentation on Saturday, May 15 entitled: "Weight Loss With Controlled-Release PHEN/TPM Drives Improvement in Comorbidities in Overweight and Obese Subjects."
"The CODHy clinical congress is an excellent opportunity for us to share the potential of Qnexa with the global medical community," stated Wesley Day, vice president, clinical development at VIVUS. Dr. Garvey's presentation illustrates the promise of Qnexa for the treatment of obesity and its effect on weight-related co-morbidities, including diabetes and high blood pressure. There is mounting clinical and scientific evidence solidifying the link between obesity and important cardiovascular and metabolic disease. We are pleased to be able to share this exciting data at an international meeting."
Following are details about the upcoming presentation:
The 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy), Hilton Prague, Czech Republic
Date and Time: Saturday, May 15, 2010, 1:55-2:05 PM
Session: Session 18A
Presentation Title: Weight Loss With Controlled-Release PHEN/TPM Drives Improvement in Comorbidities in Overweight and Obese Subjects
Abstract: 829188
Location: Hall A
Presenter: Timothy Garvey, MD
About VIVUS
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's lead product in clinical development, Qnexa®, has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor for the treatment of erectile dysfunction. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2009 and periodic reports filed with the Securities and Exchange Commission.
CONTACT:
VIVUS, Inc.
Investor Relations:
The Trout Group
Timothy E. Morris
Brian Korb
Chief Financial Officer
646-378-2923
650-934-5200
Media Relations:
Pure Communications, Inc.
Dan Budwick
973-271-6085
SOURCE VIVUS, Inc.
BrainStorm Announces Significant Milestones Achieved and 2009 Review
Date : 05/11/2010 @ 7:00AM
Source : Business Wire
Stock : BrainStorm Cell Therapeutics Inc. (BCLI)
Quote : 0.29 0.0 (0.00%) @ 2:05AM
BrainStorm Announces Significant Milestones Achieved and 2009 Review
BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics provided today a review of fiscal 2009 and an update of its significant milestones achieved.
“Fiscal 2009 was an important year for BrainStorm,” stated Chaim Lebovits, President of BrainStorm. “During 2009 we completed our ALS pre-clinical trials in accordance with Good Manufacturing Practice standards at the facility of Protein Production Services Limited and in 2010 we entered into a collaborative agreement with Hadassah Medical Center to conduct our ALS clinical trials at the Hadassah Ein Kerem Hospital.”
“In addition, during fiscal 2009 and the first quarter of 2010 the Company strengthened its balance sheet and secured new capital from investors,” continued Mr. Lebovits. “The money raised will allow us to fund the first phase of our clinical trials and sustain us through the end of the fiscal 2010 and into the start of fiscal 2011.”
“Fiscal 2010 will be a pivotal year for the Company as we expect to begin our ALS clinical trials in the coming months. We are now working in our laboratory at Hadassah preparing for these clinical trials. We started testing our growth mediums at the laboratory and expect to conclude our tests in the next few weeks. We anticipate the start of the ALS clinical trials shortly thereafter once we receive approval from the National Helsinki Committee of Israel’s Ministry of Health,” concluded Mr. Lebovits.
Fiscal 2009 and 2010 Year-to-Date Highlights
On March 4, 2009, scientists from the Tel Aviv University published research in the online edition of “Stem Cells and Development” demonstrating that human-derived adult Stem Cells may be induced to differentiate in vitro into neural-like cells and, once injected into the brain, improve impaired motor behavior in an experimental model of Parkinson's disease. These findings were a major breakthrough and demonstrated the potential promise of BrainStorm’s technology, which induces human adult stem cells to become cells that release Neurotrophic Factors.
On August 24, 2009, the Company announced that it received funds in the form of a prestigious grant from the Israeli government’s Office of the Chief Scientist as well as from a private investment. These capital infusions demonstrated a financial vote of confidence in the Company’s breakthrough stem cell technology and provided the funding to complete the ALS pre-clinical trials at Protein Production Services Ltd.
In October 5, 2009, the Company announced that bone marrow cells taken from ALS patients were capable of differentiating into nerve-supporting cells. The company tested ALS patients' bone marrow stem cells in order to confirm that these stem cells could undergo BrainStorm’s differentiation procedure to secrete NeuroTrophic Factors (NTF) and used for treatment by back transplantation into the patients. The experiments performed at BrainStorm’s research laboratories showed that the stem cells isolated from the bone marrow of healthy donors and ALS patients were similar, as indicated by all the morphological and biochemical parameters tested. In addition, the cellular expansion potential of stem cells from the healthy donors and from the patients was comparable. Most important, cells from both, the healthy donors and the patients, secreted NeuroTrophic Factors after applying Brainstorm’s unique differentiation protocols.
On October 19, 2009 BrainStorm was selected to present at the Israeli Presidential Conference: Facing Tomorrow 2009 – Tomorrows Industries Exhibition as one of the innovators in the stem cell industry recognizing the accomplishments of the Company.
On November 9, 2009 announced that in a scientific paper published in the Israel Medical Association Journal scientists from Tel Aviv University showed the migratory capacity of Neurotrophic Factor Stem Cells (NTF-SC) in animal models of Parkinson’s disease and Huntington disease. The study demonstrated that in a rat model for Parkinson’s disease, the efficacy of NTF-SC was superior to that of mesenchymal stem cells in terms of behavioral, biochemical and histological indices. This study demonstrated that Brainstorm’s approach in differentiating adult mesenchymal stem cells into NTF-SC, will provide the most effective approach for the treatment of neurodegenerative diseases via the use of stem cells.
On November 16, 2009 announced that in a scientific paper published in the Journal of Molecular Neuroscience scientists from Tel Aviv University studied the effectiveness of human bone marrow derived stem cells induced to differentiate and secrete neurotrophic factors (NTF-SC) as compared to the use of non-differentiated stem cells in a mouse model of Multiple Sclerosis (MS). This study demonstrated that the transplantation of the NTF-SC, based on our novel differentiation technology, resulted in a delay of disease onset and increased animal survival in the mouse MS model to a greater extent than transplantation of the non-differentiated stem cells. It was shown that the NTF-SC modulate the immune system and protect neuronal cells from toxic insults. The positive results in the mouse MS model demonstrated that our technology may provide an effective strategy not only for the treatment of ALS and Parkinson’s disease but also for the treatment of MS.
In January 2010 the Company received visits from the Israeli Minister of Science and Technology, the Israeli Minister of Industry, Trade and Labor and the Israeli Chief Scientist. These visits demonstrated the importance of the work that the Company is doing.
On February 17, 2010 the Company announced that it raised $1.5 million from three investors.
On February 22, 2010 the Company announced that it entered into a collaborative agreement with Hadassah Medical Center to conduct its ALS clinical trials at the Hadassah Ein Kerem Hospital.
On February 23 and 24, 2010 the Company was featured on MSNBC and Fox News.
On April 14, 2010 the Company announced the appointment of Avi Israeli to Chairman of the Board of Directors. Professor Israeli, is a Medical Doctor specializing in Internal Medicine and in Health Care Management. He has previously served as the Director General of the Israeli Ministry of Health, as well as the Director General of The Hadassah Medical Organization. He currently heads the Department of Health Policy, Health Care Administration and Health Economics at Hebrew University and Hadassah Medical School and the School of Public Health.
About BrainStorm Cell Therapeutics, Inc.
BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The patent pending technology is based on discoveries made by the scientific team led by Professor Eldad Melamed, former Head of Neurology at Rabin Medical Center, and cell biologist Prof. Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical Research Center of Tel-Aviv University. The technology allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The Company's current focus is on ALS, although its technology has promise for treating several other diseases including MS, Huntington's disease and stroke.
Safe Harbor Statement
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. The Company does not undertake any obligation to update forward-looking statements made by us.
From Thursday's Globe and Mail
Published on Wednesday, May. 05, 2010 8:26PM EDT
Last updated on Wednesday, May. 05, 2010 8:52PM EDT
Canadian researchers have discovered a link between ovarian hormones and breast stem-cell growth, a finding that appears to set the stage for the development of breast cancer.
The research, published in the journal Nature, adds to the body of knowledge of how breast cancer develops. Earlier studies have suggested a link between ovarian hormones and breast cancer, and there is mounting evidence that stem cells act as the seed for breast cancer.
With this study, researchers show that the hormone progesterone alters breast stem cells and how a woman’s reproductive history is a risk factor for the disease taking root.
“Stem cells in the adult females were thought to be inactive and constant in number. Now we make a very fundamental observation really showing that ovarian hormones during reproductive cycles alter breast stem-cell numbers,” said principal investigator Rama Khokha, a molecular biologist at the Ontario Cancer Institute and the Campbell Family Cancer Research Institute at the Princess Margaret Hospital.
“This fundamental observation opens up new ways of thinking … into the mechanism that may underlie how hormones may be linking to that increased risk of breast cancer.”
A growing body of research suggests that abnormal stem cells, which can multiply without limit, are the seed cells behind several kinds of malignancies – including cancers of the breast, brain, pancreas and ovaries.
Studies have also indicated that women who menstruate early and women who reach menopause later in life, and as a result have more reproductive cycles, are at increased risk for breast cancer. But it was not known how progesterone levels were involved in this risk – until now.
Dr. Khokha and her team found that when progesterone levels peak during the second half of the menstrual cycle, a cross-talk is triggered between the breast stem cells and the neighbouring cells. That causes increased activity and expansion in normal breast stem cells.
“The expansion is really quite surprising. It’s more than a tenfold expansion,” Dr. Khokha said.
Purna Joshi, lead author of the study and a graduate student, said the increased activity can allow for mutations that can transform cells into cancer cells.
“The stem cells are considered to be the seeds for the initiation of breast cancer. So identifying signals and factors that govern stem cell numbers is actually key to identifying new ways of targeting those stem cells,” Ms. Joshi said.
With a new understanding of how the hormone progesterone changes stem cells, the researchers say that further study will allow for new ways to target abnormal stem cells, which appear to be resistant to standard cancer therapies.
The idea that stem cells play a role in cancer is relatively new. Usually, stem cells are cast as stars in science. Some scientists have great hopes for stem cells because they have the ability to turn into every specialized cell that make up the human body. The human embryo is a plentiful source of stem cells. But as the body takes shape and matures, they become scarcer. Researchers hope that they may be able to treat a variety of diseases and repair damaged organs if they can harvest the relatively short supply of stem cells in the adult body.
But other researcher teams have uncovered evidence that stem cells also have a dark side. Their ability to reproduce infinitely could help explain the uncontrolled growth of cancerous tumours.
The cancer stem cell hypothesis is not universally accepted. But the new study goes a long way to explaining how the interaction of hormones and stem cells could give rise to breast cancer.
Densie Richards and Stem Cells http://www.cvnhealth.com/?paged=2
Stem cell 'reboot' promising as MS cure
Chemotherapy and stem-cell injection tested in Ottawa
By Dalson Chen, Windsor StarMay 2, 2010
A patient receives chemotherapy treatment in a file photo.Photograph by: Chris Hondros, Getty ImagesWINDSOR, Ont. — Ottawa doctors, who claim a new medical technique can cause a “very long-lasting remission,” are giving hope to multiple sclerosis patients.
“The inflammatory nature of the disease has virtually ceased in everyone who has received this transplant,” said neurologist Dr. Mark Freedman, who led the study with bone marrow transplant specialist Dr. Harold Atkins.
Freedman said he’s hesitant to say that the transplant of bone marrow stem cells can “cure” multiple sclerosis.
“I hate to use the C-word ... but we’ve induced a very long-lasting remission,” he said.
Aaron Prentice, 35, said he has been “blessed” to be part of the study, which investigates the theory that a person’s immune system can be reset.
Stem cells are harvested from the patient’s blood. Next, the patient’s immune system is destroyed through intense chemotherapy. Then the stem cells are reintroduced with the hope that when the immune system grows back, it will no longer attack the nervous system.
“Kind of like rebooting a computer,” said the Windsor man.
Multiple sclerosis causes the body’s own immune system to attack the fatty myelin sheaths that surround the axons that transmit electrical signals between the nerve cells in the brain and spinal cord. This hampers the ability of the cells to communicate, leading to a weakening and wasting of the muscles.
Freedman and Atkins plan to release the results of the research later this year.
Prentice was living in British Columbia and working as a plumber when he first started experiencing some of the symptoms of multiple sclerosis: dizziness, loss of balance, difficulty walking, blurred vision.
He was 24 when he lost sight in one eye, leading to a conclusive diagnosis in 1999.
“It was definitely a shock,” he said.
Prentice learned of the stem cell transplant study through his neurologist.
Prentice said he has experienced no complications, and even his hair — lost during chemotherapy — is growing back. Most importantly, his symptoms have not worsened.
“The study is aimed to stop the progression more so than repair the damage already done,” Prentice said.
“Some cases have shown improvement afterwards, and I’m hopeful for that. But, at this point, I’m happy if it does not progress anymore.”
The treatment was only available in Canada through the Ottawa medical study. Prentice was the last of 24 patients who volunteered as trial subjects.
Part of the criteria for joining the study — launched in October 2000 — was that the patients have aggressive multiple sclerosis and were likely to become severely disabled.
The MS Society of Canada, which funded the study, states that the bone marrow transplants have generally been “well tolerated.”
But officials also warned that “each step of this treatment carries a risk of serious complications. These may be severe enough in a small percentage of patients to be fatal.”
One trial subject died as a result of liver toxicity, leading to changes in the study’s protocol.
Windsor Star
© Copyright (c) Canwest News Service
Read more: http://www.vancouversun.com/health/Stem+cell+reboot+promising+cure/2978600/story.html#ixzz0mra6zTMg
Search for stem cells for ALS trials had to go outside state
By Ryan Beene
Dr. Eva Feldman had to turn to a company outside Michigan for the stem cells needed for her ongoing Phase I trials on patients with Lou Gehrig's disease.
She chose Neuralstem Inc. (AMEX: CUR), a Rockville, Md.-based company focused on developing treatments for currently incurable neurological disorders.
Feldman said Neuralstem's stem cells are more developed than cells available at the University of Michigan because of the ban on research in Michigan before the 2008 passage of Proposal 2.
She said she plans to use Neuralstem's cells for a future Alzheimer's trial, too.
Using stem cells developed at UM would have delayed the Lou Gehrig's trials by three to five years, Feldman said.
Neuralstem will retain the intellectual property rights for the stem cell technology, but the university has first-publication rights for the results of the Lou Gehrig's disease trial.
Feldman said UM is developing its own neural progenitor cells that will be able to be used instead of Neuralstem cells in the future.
The university could manufacture these cells at its North Campus Research Center, the former Pfizer complex in Ann Arbor.
Geron Corporation Hope is rekindling for embryonic stem-cell research, but don’t expect rapid results
Greg Burns
May 3, 2010
When embryonic stem cells were first hailed as a revolutionary medical breakthrough more than a decade ago, the list of potential cures ran from Alzheimer's and Parkinson's to cancer and heart disease.
Severed spines would be healed, and immune disorders sent into permanent remission.
Then came a decade of political gamesmanship and deeply felt ethical concerns, relentlessly nudging the promising science toward the sideline.
Now, as the BIO International Convention opens Monday in Chicago, hope is rekindling for embryonic stem-cell research. All the possibilities dreamed about long ago may yet come to pass — eventually.
Last week, the National Institutes of Health approved 13 embryonic cell lines for use by federally funded researchers, freeing those biological tools from a limbo of red tape. With dozens of additional cell lines on the verge of approval as well, shares of such leading stem-cell companies as Geron Corp. edged higher.
"It is definitely good news," said Erik Forsberg, executive director of the WiCell Research Institute, a stem-cell source and service in Madison, Wis. "This has been a huge issue for researchers."
If the past is any guide, it will be a huge issue for the technology's opponents as well, who doubt its efficacy as well as its morality.
Embryonic stem cells ran into trouble from the start. First isolated in the late 1990s, they hold the incredible potential to transform into completely different cells, treating disease or replacing damaged tissue.
Fertility-clinic leftovers provided a ready source of genetic material. But the destruction of human embryos in the name of science prompted an outcry.
Not long after he took office, former President George W. Bush restricted federal funding to only certain existing embryonic cell lines. Bush is slated to speak at the BIO conference Tuesday, along with former President Bill Clinton.
Those restrictions on embryonic cell lines helped to encourage research into cells derived from adults, which proved more adaptable than originally suspected. Even the Vatican supports adult-cell experiments, because they don't involve embryos. But recent results suggest adult cells die sooner and may be less useful than hoped.
Researchers applauded when President Barack Obama lifted the Bush ban last year. His executive order directed the NIH to develop guidelines for approving stem-cell lines, however, and the agency's paperwork took time.
As a result, some cell lines that had been OK'd under Bush and widely used over the previous decade faced new uncertainty about whether the NIH would approve them.
NIH Director Dr. Francis Collins alluded to those worries last week, saying his agency's latest decision provides "welcome reassurance … that valuable work will not be lost."
The action from NIH puts a spotlight on a somewhat scanty stem-cell program at the BIO conference, which attracts exhibitors across all aspects of biotechnology. A decade of scrutiny has taught researchers to use the term "embryonic" sparingly, and it appears only nine times in the voluminous conference program.
Still, the government lists hundreds of stem-cell-related clinical trials, and their promise goes beyond therapeutic purposes. They could, for instance, be used in disease modeling to advance new drugs.
"It's not as sexy as using stem cells for a miracle cure, but it could be just as important," said Kalah Auchincloss, a Washington, D.C., attorney moderating a panel on stem-cell regulation at the BIO conference Tuesday. "There are really exciting things going on behind the scenes. Things are in the pipeline."
Some embryonic stem-cell research has made it front and center. A human clinical trial could start this year for a Geron treatment that restored spinal function in paralyzed rats. That would put the technology's effectiveness to the test while also, inevitably, reviving worries about the sanctity of life and irrevocable nature of the treatment.
Even if political and ethical concerns were absent, though, no one should expect rapid results, Auchincloss said. "I think it's just the nature of science. It's not immediate."
gburns@tribune.com
2010 BIO International Convention
The Biotechnology Industry Organization is holding its annual meeting this week at McCormick Place.
What:
The conference will include panel discussions on developments in industrial and agricultural biotechnology, economic impact of biosciences on states, partnerships in drug and vaccine development, and efforts to help underserved populations.
When:
Monday through Thursday
Keynote speakers:
U.S. Surgeon General Dr. Regina Benjamin will deliver a speech Monday. Former Presidents George W. Bush and Bill Clinton are scheduled to speak Tuesday. The event is not open to the public. Former Vice President Al Gore will speak Wednesday.
Vivakor Expands Market for VivaThermic Technologies to Genetic and Stem Cell Reagent Consumables and Further Increases Revenue O
Date : 04/30/2010 @ 2:23PM
Source : GlobeNewswire Inc.
Stock : Vivakor, Inc. (VIVK)
Quote : 0.175 0.092 (110.84%) @ 9:28AM
Vivakor Expands Market for VivaThermic Technologies to Genetic and Stem Cell Reagent Consumables and Further Increases Revenue O
CORALVILLE, Iowa, April 30, 2010
GLOBE NEWSWIRE
Vivakor, Inc. (OTCBB:VIVK) announced new markets for its VivaThermic technologies and further increased revenue projections for its VivaThermic division. These new markets include gene amplification applications and similar uses where temperature control is especially critical. Speaking about these new genetic applications, Dr. Tannin Fuja, Vivakor's CEO and Chief Scientific Officer, said, "Thermo-cycling and other temperature sensitive reactions have become common in nearly every biological laboratory. VivaThermic products improve temperature control of these reactions and will improve sensitivity and save time."
Additionally, VivaThermic technologies are being marketed as the best bio-consumable container for biological and stem cell related reagents which must be stored in temperature controlled environments. Dr. Fuja stated, "The global market of consumables for temperature sensitive reagent shipment, handling and storage is already enormous and continues to grow." This announcement will expand upon Vivakor's recently released revenue projections for its VivaThermic division estimated at $20 million annually.
About Vivakor, Inc.
Vivakor™ is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds that extend or improve life. More information can be found about Vivakor at www.vivakor.com.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's products and their related market potential. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.
CONTACT: Vivakor, Inc. Investor Relations c/o IME Advisors (888) 648-8485
Research into stem cells of adults stirs hopes
Read more: http://www.kentucky.com/2010/04/28/1242732/research-into-stem-cells-of-adults.html#ixzz0mV97cvC3
http://www.kentucky.com/2010/04/28/1242732/research-into-stem-cells-of-adults.html
FDA’s position on adult stem cells
http://cellmedicinesociety.org/faq
Please take the time to send off the suggested note towards the end of the article.
FDA’s position on adult stem cells is contained in multiple places and can be tough to decipher.
Basically, to treat disease, your adult stem cells need to be grown a bit ( incubated) in culture. If you don't do this, the stem cells are unlikely to help the patient. However, FDA's current regulatory framework makes this type of cell culture the manufacture of a new drug, essentially removing cell therapy from your doctor black bag (until the FDA approves your stem cells as drugs for each and every medical condition). So while your doctor could do all of this safely in a physician run lab and begin treating a host of diseases, you have to wait 5-20 years for access to your own stem cells (as a drug).
So what's the public health rationale for why you would want to regulate the patient's own stem cells as a drug? If we look at mass production of anything such as food, drugs or someone cells placed in a vial, the public health implications can be tremendous. A bad batch of food or drugs can make allot of people very sick very quickly. However, an autologous procedure is very different, in that it involves taking one person's tissue and placing it back into the same person. For example, disease transmission risks from one person to another don't apply; the idea of one "bad batch" of anything making many people sick doesn't apply. The worst that can happen is that one person gets sick from something that happened to their own tissue. This is therefore not something for mass production rules, but rather things like professional treatment guidelines and implantation registries.
As we have been discussing, the FDA’s position on your adult stem cells is that they are biological drugs. How did this happen? FDA’s definition of stem cells (a type of ‘”human cell, tissue, or cellular or tissue-based products” (HCT/Ps)) is found at 21 CFR § 1271.3(d).
As revealed HERE, that definition has undergone a very significant change over the past five years. Originally, HCT/P was defined as follows: “any human tissue derived from a human body and intended for transplantation into another human…” Now, however, HCT/P is defined as “articles containing or consisting of human cells or tissues that are intended for implantation, transplantation, infusion, or transfer into a human recipient.” Thus, the regulation currently in effect purports to give FDA the authority to regulate even those tissue products being used for autologous purposes (i.e. tissue products being used in a bypass surgery), and therefore gives the FDA more authority than Congress has ever authorized. Congress does not hide elephants in mouse holes, and it has never granted FDA the authority to regulate the practice of medicine.
Why is this important? The FDA made these changes to the law without public comment. Federal law provides that the FDA cannot make new regulations without noticing the public and offering the public the opportunity to comment. In this case, had the FDA noticed the public of a proposed change to 21 CFR § 1271.3(d), the proposed change would have infuriated doctors and others involved in medical procedures because the new regulation purports to give the FDA authority to regulate the practice of medicine.
Why make this change? What was in it for FDA? By changing one simple phrase, the agency has given itself new sweeping powers to regulate stem cells as biological drugs. In fact, the very existence of CBER (the cell based therapy group at FDA) depends on this little change of phrase. Without it, the FDA has no authority to regulate the patient’s own stem cells as a drug. But with it, FDA gives itself unheard of authority and a whole new section of the federal government has a reason to exist.
Please take a minute right now to send the following to the FDA/Ombudsman (feel free to edit/add your own comments):
Dear sirs,
I oppose the change made in 21 CFR § 1271.3(d) from “any human tissue derived from a human body and intended for transplantation into another human…” (2004 and prior) to “articles containing or consisting of human cells or tissues that are intended for implantation, transplantation, infusion, or transfer into a human recipient.” (recent regulation). This change allows FDA to regulate the practice of medicine, even though Congress never gave the FDA such power. Please put this regulation change to public comment as is required by law.
New stem-cell therapy for dogs Published: 8:04PM Tuesday April 27, 2010
Source: NZPA
Read
Source:
New Zealand dog owners will soon be able to access breakthrough stem cell therapy for their pets suffering from degenerative joint disease.
Pet Doctors, New Zealand's biggest companion animal veterinary group, has announced an agreement to treat dogs with stem cell technology. New Zealand will be only the third country in the world to offer this type of therapy for dogs, along with Australia and the United States.
Pet Doctors group chief executive Steve Merchant says the treatment offers an alternative for thousands of dogs suffering from degenerative joint disease.
"Many pet-owners have experienced the heartache of seeing a previously active dog deteriorate in mobility - for simple things like getting into the car, going for walks, or having a play at the beach.
"Often the mind is willing but the body is not," says Merchant.
"By using the dog's own fat cells and genetic material to regenerate their joint, they can lead healthier and more active lives without drugs."
The therapy uses advanced technology and the dog's own natural regeneration system to treat painful arthritic joints. It is a one-day procedure that involves implanting stem cells into affected joints.
Advertisement
Merchant says the technology is very exciting and could soon be a routine procedure offered throughout the country.
"It is expensive and it's not for every dog but it will help in many cases. Dogs are living longer and owners are forming closer bonds to their animals so there will be a demand for this treatment."
Currently the therapy is being offered in Australia at the cost of around $6000. More than 200 dogs have been operated on in Australia so far, with excellent results. So far there have been three procedures carried out in New Zealand.
The majority of dogs showed a reduction in pain within 10 days, and have maintained an improvement 22 months after treatment.
MultiCell Technologies Is Granted European Patent for the Treatment of Cancer
Date : 04/26/2010 @ 8:00AM
Source : PR Newswire
Stock : Multicell Techs (BB) (MCET)
Quote : 0.009 0.0 (0.00%) @ 2:05AM
MultiCell Technologies Is Granted European Patent for the Treatment of Cancer
MultiCell Technologies Is Granted European Patent for the Treatment of Cancer
PR Newswire
WOONSOCKET, R.I., April 26
WOONSOCKET, R.I., April 26 /PRNewswire-FirstCall/ --
MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) announced today that it has been granted a European patent (EP 1539819B1) covering certain of its therapeutic candidates for the treatment of cancer.
Increasing evidence suggests that the immune system regulates the development of cancer by several mechanisms. This regulation can be either beneficial through immunosurveillance and the destruction of cancer cells, or detrimental by facilitating tumor growth by shaping the immunophenotype of tumors, creating an immunosuppressive environment, or inducing regulatory T-cells.
MultiCell has created a new class of recombinant antibody therapeutics which redirect the immune response to specific cancer targets corresponding to the peptides engrafted onto the recombinant antibody. Such compositions are able to transform seemingly ineffective peptides into potent antibody therapeutics with a different mechanism of action compared to that of conventional antibody therapeutics currently in clinical use. These recombinant antibody therapeutics not only produce a potent immune response, but also stimulate the generation of cytolytic cells, and Interferon-gamma and Interleukin-2 producing T-cells. When coupled with MultiCell's dsRNA therapeutics, this new class of recombinant antibody therapeutics has been shown in animal models to eradicate cancer and generate immune protection against the reoccurrence of malignant tumors.
"We are very pleased that the European Patent Office has decided to grant us a patent covering our novel compositions and method for the treatment of cancer as well as for the treatment of infectious disease," stated Jerry Newmin, Chairman and Chief Executive Officer of MultiCell Technologies. "Our technology uses the antibody molecule as a platform to better present a peptide to immune cells thereby increasing the overall immune response to the peptide," Mr. Newmin added.
MultiCell also owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), one U.S. patent application (U.S. 2006/0019387A1), and several corresponding issued and pending foreign patents and patent applications related to the isolation and differentiation of liver stem cells. The role of liver stem cells in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. In addition, liver cancer and cancerous stem cells specifically, are amenable to targeted therapeutic approaches including peptide-directed immunotherapy.
Primary liver cancer begins in the cells of the liver itself. According to the National Cancer Institute (NCI), in 2008 there were approximately 21,400 new cases of primary liver cancer and intrahepatic bile duct cancer in the United States, and approximately 18,400 of those cases resulted in death. Hepatocellular carcinoma, resulting from Hepatitis B and Hepatitis C infection, is the most common cancer in some parts of the world, with more than 1 million new cases diagnosed each year. The NCI also reports that hepatocellular carcinoma is associated with cirrhosis of the liver in 50% to 80% of patients.
Caution Regarding Forward-Looking Statements
Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe", "will", "expect", "anticipate", "estimate", "intend", "plan", "forecast", "could", and "would". Examples of such forward looking statements include statements regarding the timing, design, scope, and anticipated results of our clinical development programs. MultiCell bases these forward- looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our products as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-K for the fiscal year ended November 30, 2009, and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and each assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events
SOURCE MultiCell Technologies, Inc.
Blind Girl get's cure you need to see to believe"
Stem Cells can repair bulging disks
these are great ideas for humans. need to advance from mouse trap.
Single Gene Is Responsible for OCD-like Behaviors in Mice
By Weill Cornell Medical College
Apr 25, 2010 - 2:59:19 PM
(HealthNewsDigest.com) - NEW YORK -- Researchers at the Ansary Stem Cell Institute and the Department of Psychiatry at Weill Cornell Medical College discovered that mice missing a single gene developed repetitive obsessive-compulsive-like behaviors. The genetically altered mice, which behaved much like people with a certain type of obsessive-compulsive disorder (OCD), could help scientists design new therapies for this debilitating condition.
The researchers made this serendipitous discovery while looking at the role of a gene, called Slitrk5, which they had earlier linked to blood stem cells and vascular cells. In the April 25 online edition of Nature Medicine they report how, in follow-up studies, mice in which the gene was disabled ("knocked-out") demonstrated obsessive self-grooming and extreme anxiety. Further study showed that the frontal lobe-to-striatum circuitry of the brains of these mice were altered in the same ways that are implicated in OCD in humans.
This discovery links Slitrk5 to development of OCD-like behaviors, and offers scientists a new mouse model of the disorder, say the study's senior co-investigators, Dr. Shahin Rafii and Dr. Francis S.Y. Lee. Dr. Rafii is director of the Ansary Stem Cell Institute and professor in genetic medicine Weill Cornell Medical College and and an HHMI investigator. Dr. Lee is associate professor of psychiatry and pharmacology at the Medical College.
"Overall, our data suggest that Slitrk5 may have a central role in the development of the core symptoms of OCD -- self-injurious, repetitive behavior and increased anxiety," Dr. Rafii says. "Very few psychiatric disorders have been linked to a single gene, and it will be important to find out if patients with the disorder have an alteration of Slitrk5."
The findings may help scientists better understand both development and treatment for one or more of the several different types of human OCD behaviors, say Drs. Sergey Shmelkov and Adília Hormigo, the study's co-lead authors and members of the Ansary Stem Cell Institute. Dr. Shmelkov is an assistant research professor of genetic medicine, and Dr. Hormigo is an assistant professor of neurology at Weill Cornell Medical College and a neurologist at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.
"We can't draw direct parallels between mice and humans, because OCD behavior in mice shows up as excessive self-grooming, and in humans there is a broad spectrum of behaviors, from hand-washing to other compulsive actions as well as obsessive thoughts," says Dr. Lee. "But our finding of altered brain functioning suggests a very strong link at this point to some of the issues seen in humans."
The research team cannot say why a gene found in blood stem cells and vascular cells could be implicated in a behavioral brain disorder, but they speculate that "cross-talk" between the vascular system in the brain and neurons in brain tissue may be the link.
Dr. Rafii and his colleagues had previously identified Slitrk5 in the progenitor stem cells that create blood, and they subsequently demonstrated that the protein created by this gene is expressed in leukemia, embryonic stem cells, and in subsets of endothelial cells, which are the basic building blocks for the circulatory system.
In this study, the researchers were looking at the effects created when the Slitrk5 gene was "knocked out" in laboratory mice and replaced with a "reporter" gene. "We did this because we wanted to look at the effect on the blood system, which is what we are primarily interested in," says Dr. Shmelkov. "But we didn't find anything, which was frustrating."
But then Dr. Shmelkov and Dr. Hormigo noticed that some of the knockout mice began to develop facial lesions, and over time, all of the mice without Slitrk5 eventually developed the same skin issues. They also noticed that the mice were hyperactive and seemed to groom themselves a lot. The researchers videotaped this behavior and quantified it, and found that the knockout mice groomed themselves significantly more than did wild-type mice, which served as the experimental control. A set of follow-up experiments with scientists from Dr. Lee's laboratory, Dr. Kevin Bath and Iva Dincheva, concluded that the mice were also considerably more anxious compared with control mice.
The scientists gave Prozac, a standard drug used in the treatment for patients with OCD, to both sets of mice, and found that excessive grooming stopped completely in the experimental animals. "Now that we have this mouse model, we can test new therapies for OCD that can ultimately be applied to humans," says Dr. Hormigo. "We know Prozac works to ameliorate some OCD symptoms in humans -- the drug also worked for our OCD mice -- but the effect can be temporary and more targeted treatments are needed."
The researchers then looked at brain function in the mice. By examining activity of the reporter gene that was substituted for Slitrk5 in knockout mice, they found that the gene was active throughout the brain, but excessively active in one part of the frontal cortex. Dr. Francis Lee's group, which included co-lead authors Dr. Deqiang Jing and Catia Proenca, then performed sophisticated analyses and discovered structural abnormalities in a related brain region, the striatum, an area of the brain involved in reward and decision-making. Neurons within the striatum were less complex than in normal brain tissue, which is an issue because these neurons act like a hub that receives and transmits input to and from the cortex, says Dr. Jing. Further investigation demonstrated that the level of glutamate receptors in these particular neurons was decreased, compared with control mice. "These molecular findings suggest that this gene plays a unique, unexpected role in modifying glutamate neurotransmission in this particular circuit," says Ms. Proenca.
Other researchers have created mouse models of other types of OCD as recently as 2007. However, for the first time, the findings involving Slitrk5 by Drs. Rafii, Lee and their teams are consistent with imaging studies in humans with OCD that implicate dysregulation of corticostriatal circuitry in the disorder.
"This work is an unexpected off-shoot from stem cell science into the realm of psychiatry, and could potentially have major application for treatment of neuropsychiatric diseases," says Dr. Rafii.
In addition to scientists from Weill Cornell Medical College, researchers from Memorial Sloan-Kettering Cancer Center; the Instituto Gulbenkian de Ciência, Oeiras, Portugal; Regeneron Pharmaceuticals, Tarrytown, N.Y.; and New York University's Langone Medical Center contributed to the work.
The study was funded by the National Institutes of Health, Burroughs Wellcome Foundation, International Mental Health Research Organization, the Sackler Institute for Developmental Psychobiology, DeWitt-Wallace Fund of the New York Community Trust, Pritzker Consortium, National Alliance for Research on Schizophrenia and Depression, Mildred-Scheel-Stiftung, Deutsche Krebshilfe, Gulbenkian Institute of Science, Fundação para a Ciência e a Tecnologia, Howard Hughes Medical Institute, Ansary Stem Cell Institute, Anbinder Foundation, Newman's Own Foundation, Qatar National Priorities Research Program, Empire State Stem Cell Board, and a grant from the New York State Department of Health.
Ansary Stem Cell Institute
The Ansary Stem Cell Institute, established at Weill Cornell Medical College in 2004 through the generous donation of Shahla and Hushang Ansary, brings together a premier team of scientists to focus on stem cells -- the primitive, unspecialized cells with an unrivaled capacity to form all types of cells, tissues and organs in the body. The vision of the Ansary Institute is to help lead the way in 21st-century medicine by employing this new field of research with tremendous potential to relieve human suffering. The Institute permits the multidisciplinary collaboration and creativity of Weill Cornell's researchers, as well as helps to attract the best and brightest young researchers in the field. Scientists at the Institute hope to discover the wellspring of adult stem cells in the body and ways to manipulate them to treat human illness. In particular, they hope to understand the regulation of cells that give rise to such essential components as blood vessels, insulin-producing cells in the pancreas (which are damaged in diabetics), and neurons of the brain and nervous system.
Weill Cornell Medical College
Weill Cornell Medical College, Cornell University's medical school located in New York City, is committed to excellence in research, teaching, patient care and the advancement of the art and science of medicine, locally, nationally and globally. Physicians and scientists of Weill Cornell Medical College are engaged in cutting-edge research from bench to bedside, aimed at unlocking mysteries of the human body in health and sickness and toward developing new treatments and prevention strategies. In its commitment to global health and education, Weill Cornell has a strong presence in places such as Qatar, Tanzania, Haiti, Brazil, Austria and Turkey. Through the historic Weill Cornell Medical College in Qatar, the Medical College is the first in the U.S. to offer its M.D. degree overseas. Weill Cornell is the birthplace of many medical advances -- including the development of the Pap test for cervical cancer, the synthesis of penicillin, the first successful embryo-biopsy pregnancy and birth in the U.S., the first clinical trial of gene therapy for Parkinson's disease, and most recently, the world's first successful use of deep brain stimulation to treat a minimally conscious brain-injured patient. Weill Cornell Medical College is affiliated with NewYork-Presbyterian Hospital, where its faculty provides comprehensive patient care at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. The Medical College is also affiliated with the Methodist Hospital in Houston, making Weill Cornell one of only two medical colleges in the country affiliated with two U.S.News & World Report Honor Roll hospitals. For more information, visit www.med.cornell.edu.
Subscribe to our FREE Ezine and receive current Health News, be eligible for discounted products/services and coupons related to your Health. We publish 24/7.
HealthNewsDigest.com
For advertising or promotion, email: tvmike13@healthnewsdigest.com
Leftover' veins from heart surgery yield stem cells
Stem cells were taken from a vein
Human veins left over from lifesaving bypass surgery could be a source of "master" cells to help treat future heart problems, say scientists.
A University of Bristol team extracted stem cells from the veins, then used them to stimulate new blood vessel growth in mice, Circulation reports.
The researchers say their findings could bring treatments to repair damaged heart muscle one step closer.
However, a stem cell expert warned that they remained some years away.
Stem cells are attractive to medical researchers because they have the ability to produce many different types of human cell, opening up the possibility of repair or renewal for tissues ravaged by disease or injury.
While human embryos were originally seen as the prime source of "pluripotent" cells, with the potential to form virtually any tissue type, scientists are increasingly finding ways to isolate cells from adults which have some of these properties, and encourage them to multiply into useful numbers.
The latest discovery uses a "waste" product from thousands of operations carried out on heart patients each year.
Patients with heart disease often have blocked or narrowed arteries supplying the heart muscle.
Repairing a damaged heart is the holy grail for heart patients
Professor Peter Weissberg, British Heart Foundation
The lack of blood leaves the muscle damaged, and this can cause chest pain or even a heart attack.
A heart bypass operation takes a section of vein, usually from the patient's leg, and uses it to replace a blocked or narrowed section of heart artery.
The surgeon normally takes a slightly longer section than is actually required.
In this study, the Bristol team took the leftover piece and, in the laboratory, they managed to extract "progenitor" cells from the veins and persuade them to increase in number.
Mouse muscle
When the stem cells were injected into the leg muscle of a mouse which had been deprived of blood to simulate conditions in a damaged heart, the cells appeared to trigger the development of new blood vessels and improve blood flow.
Professor Paolo Madeddu, who led the research, said: "This is the first time that anyone has been able to extract stem cells from sections of vein left over from heart bypass operations.
"These cells might make it possible for a person having a bypass to also receive a heart treatment using their body's own stem cells."
However, other experts said much more work would be needed before such cells could be used widely in humans.
Professor Qingbo Xu, from King's College London, said the mechanisms by which the cells worked needed to be more fully understood.
"It's possible this could be a future treatment, although not at the same time as the heart bypass surgery, as it takes some time to extract and grow these cells in the laboratory.
"But there is a long way to go before we can have a clinical application for this."
Professor Peter Weissberg, the medical director of the British Heart Foundation, which funded the research, said the prospect of repairing heart damage was the "holy grail" for heart patients.
He said: "It brings the possibility of 'cell therapy' for damaged hearts one step closer, and, importantly, if the chemical messages produced by the cells can be identified, it is possible that drugs could be developed to achieve the same end."
Gene silencing may be responsible for induced pluripotent stem cells' limitations
April 25, 2010 Scientists may be one step closer to being able to generate any type of cells and tissues from a patient's own cells. In a study that will appear in the journal Nature and is receiving early online release, investigators from the Massachusetts General Hospital Center for Regenerative Medicine (MGH-CRM) and the Harvard Stem Cell Institute (HSCI), describe finding that an important cluster of genes is inactivated in induced pluripotent stem cells (iPSCs) that do not have the full development potential of embryonic stem cells. Generated from adult cells, iPSCs have many characteristics of embryonic stem cells but also have had significant limitations.
Ads by Google
Stem Cell Therapy Germany - Europe's leading treatment center Licensed and government approved - www.xcell-center.com
"We found that a segment of chromosome 12 containing genes important for fetal development was abnormally shut off in most iPSCs," says Konrad Hochedlinger, PhD, of the MGH-CRM and HSCI, who led the study. "These findings indicate we need to keep improving the way we produce iPSCs and suggest the need for new reprogramming strategies."
Although iPSCs appear quite similar to embryonic stem cells and give rise to many different types of cells, they have important limitations. Several molecular differences have been observed, particularly in the epigenetic processes that control which genes are expressed, and procedures that are able to generate live animals from the embryonic stem cells of mice are much less successful with iPSCs.
Previous studies have compared iPSCs generated with the help of viruses, which can alter cellular DNA, to embryonic stem cells from unrelated animals. To reduce the chance that the different sources of the cells were responsible for observed molecular differences, the MGH/HSCI research team prepared two genetically matched cell lines. After generating mice from embryonic stem cells, they used a technique that does not use viruses to prepare lines of iPSCs from several types of cells taken from those animals. They then compared the iPSCs with the original, genetically identical embryonic stem cells.
The most stringent assay of cells' developmental potential showed that two tested lines of embryonic stem cells were able to generate live mice as successfully as in previous studies, but no animals could be generated from genetically matched iPSCs. Closely comparing RNA transcription profiles of several matched cell lines revealed significantly reduced transcription of two genes in the iPSCs. Both genes are part of a gene cluster on chromosome 12 that normally is maternally imprinted - meaning that only the gene copies inherited from the mother are expressed.
Ads by Google
Stem Cell Therapy Germany - Europe's leading treatment center Licensed and government approved - www.xcell-center.com
Examination of more than 60 iPSCs lines developed from several types of cells revealed that this gene cluster was silenced in the vast majority of cell lines. While the gene-silenced iPSCs were able to generate many types of mouse tissues, their overall developmental potential was limited. In an assay that produces chimeric animals that incorporate cells from two different stem cells, mice produced from gene-silenced cells had very few tissues that originated from the iPSCs. However, in a few iPSC lines the gene cluster was normally activated, and in the most rigorous developmental assay, those iPSCs were as successful in producing live animals as embryonic stem cells have been. The authors believe this is the first report of animals being produced entirely from adult-derived iPSCs.
"The activation status of this imprinted cluster allowed us to prospectively identify iPSCs that have the full developmental potential of embryonic stem cells," says Matthias Stadtfeld, PhD, of the MGH-CRM and HSCI, a co-lead author of the report. "Identifying pluripotent cells of the highest quality is crucial to the development of therapeutic applications, so we can ensure that any transplanted cells function as well as normal cells. It's going to be important to see whether iPSCs derived from human patients have similar differences in gene expression and if they can be as good as embryonic stem cells - which continue to be the gold standard - in giving rise to the 220 functional cell types in the human body."
Hochedlinger adds, "Previous studies in mice have shown that embryonic stem cells derived from nuclear transfer - the technique used to clone animals - are indistinguishable from stem cells derived from fertilized embryos. Nuclear transfer is another way of reprogramming adult cells into embryonic-like cells, and comparing that approach with iPSC generation may yield important insights into ways of producing the safest and highest quality pluripotent cells for use in patients." Hochedlinger is an associate professor in the Harvard University Department of Stem Cell and Regenerative Medicine.
Provided by Massachusetts General Hospital (news : web)
i don't have da link but nice article on stem cells today. gern mentioned.
stem cell fer da heart.
Michigan news: Senate passes bill to monitor stem cell research
COMPILED FROM REPORTS BY DAWSON BELL, TODD SPANGLER AND THE ASSOCIATED PRESS
LANSING: Senate passes bill to monitor stem cell research
The Michigan Senate approved legislation Wednesday to monitor and regulate research using stem cells derived from human embryos.
Backers of the measure said it was designed to implement a 2008 ballot proposal that lifted the state's ban on research that results in the destruction of embryos, and should ensure that the intent of voters who approved the measure is followed. But opponents said it is a thinly disguised effort to nullify the ballot proposal that will undermine research efforts.
The primary stem cell regulatory bill was approved 25-12, with four Democrats joining all but one Republican in the majority. But House Speaker Andy Dillon, D-Redford Township, issued a statement criticizing the legislation and suggesting the Democratic majority in the House is unlikely to act upon it.
Feds grant $30 million for energy efficiency
Michigan is to receive $30 million to retrofit buildings to make them more energy efficient, the White House said Wednesday, as part of $452 million in stimulus funds being spent on the program nationwide.
The money is to go to the Michigan Collaborative Retrofit Ramp-Up Initiative, designed to generate interest in energy efficiency improvements, educate workers and help lenders willing to invest in retrofitting buildings.
The initiative is to work through a Neighborhood Retrofit Program throughout the state and the Detroit Commercial Centers Program.
Hey, Locks...you always seem to come up with interesting news bits. Thanks... ;)
Breakthrough Research: Chinese Convert Pig Cells Into Embryonic Stem Cells
by Boomer Babe Share
image: BBC NewsThe first successful conversion of pig cells into universally usable stem cells took place at the Shanghai Institute of Biochemistry and Cell Biology under the direction of Dr. Lei Xiao. Dr. Xiao's team extracted the cells from a pig's ear and bone marrow, and found the right chemical cocktail to reprogram the cells into the three layers of cell types that make up embryonic stem cells.
You may have read about the future possibility of transplanting the vital organs of pigs into humans, because pig organs are so similar to their human equivalents. But the recent discovery of a technique to convert adult pig cells into "pluripotent" stem cells will make organ transplants from pigs, and even those from other humans, much more likely to succeed!
If Dr. Xiao's dream comes true, this discovery will not only enable greater acceptance of organ transplants by humans and potentially other animals, but facilitate many treatment and preventative procedures for humans and animals.
Regenerative medicine specialists interviewed by BBC News had mixed reactions to the news. One professor, Chris Mason. at University College London said, "This breakthrough to produce pig stem cells potentially reinvigorates the quest to grow humanised pig organs such as pancreases for diabetics and kidneys for chronic renal failure."
But Dr. Sebastien Farnaud, from the HadwenTrust for Humane Research, was naturally concerned: "Persisting with highly speculative research that would see us use sentient animals as little more that living organ grow-bags, is not only ethically unsupportable but also scientifically dubious," he said. "Creating pig stem cells does not necessarily remove the risk of organ rejection but even more worrying is the risk of infecting patients and the wider public with pig viruses."
If you would like to read the research report, it is available at the Journal of Biological Chemistry
Stem cell therapies will change medicine as we know it, but, you still need to be careful about where you get your treatments. Here is another reason why to be cautious:
http://www.cbsnews.com/video/watch/?id=6402809n&tag=related;photovideo
Thanks for the link locks...it's a good one.
Einstein receives $10 million NIH grant to expand stem cell research facilities
Einstein to increase research space and recruit new stem cell scientists
April 15, 2010 – (BRONX, NY) – Albert Einstein College of Medicine of Yeshiva University has been awarded $10 million from the National Institutes of Health (NIH) to expand its stem cell research capabilities. The funds will be used to create new laboratories in order to increase its already substantial base of stem cell investigators. This will be carried out under the auspices of the recently established Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research.
The Gottesman Institute for Stem Cell and Regenerative Medicine Research will utilize the NIH support, issued under the American Recovery and Reinvestment Act, to renovate and modernize existing research space and expand the related stem cell core facilities for cell sorting and cell transplantation. The changes will create space for several new senior stem cell investigators.
"A key aspect of our plan is to embed stem cell laboratories within easy reach of Einstein's centers in diabetes, cancer, HIV/AIDS, liver disease and women's health to encourage the free flow of science," said Harry Shamoon, M.D., associate dean for clinical and translational research. "With guidance and support from Allen M. Spiegel, M.D., and in consultation with our faculty leadership, a team from Einstein's academic administration worked with our outstanding facilities and management department to map out this plan." Dr. Spiegel is the Marilyn and Stanley M. Katz Dean.
Einstein's stem cell investigators are currently located in laboratories throughout the Jack and Pearl Resnick Campus in the Bronx. The Gottesman Institute for Stem Cell and Regenerative Medicine Research, which will house the director's laboratories in a dedicated wing of the Michael F. Price Center for Genetic and Translational Medicine/Harold and Muriel Block Research Pavilion, will also be home to the institute's administrative core, while also facilitating increased stem cell research throughout Einstein's campus.
The laboratory renovations, which will be accomplished over the next two years, focus on four broad themes: 1) stem cell biology, 2) stem cell genetics, 3) cancer stem cells, and 4) translational stem cell research. In order to best complement and build upon the work of existing Einstein stem cell researchers, the Gottesman Institute for Stem Cell and Regenerative Medicine Research will expand basic and translational stem cell research by co-recruiting new faculty in concert with multiple departments, including cell biology, genetics, developmental and molecular biology, the Dominick P. Purpura Department of Neuroscience, and others.
The renovation funds, part of President Obama's stimulus program for NIH, will create 150 new jobs, in both construction and research positions. This will be economically critical for the 1.4 million people in the Bronx, while also creating a major driver of scientific innovation to create cures for multiple diseases.
In consultation with the faculty, the grant proposal was developed by staff in the office of Dean Spiegel, in conjunction with Dr. Shamoon; Salvatore Ciampo, senior director of facilities management; Julia Herrick, former assistant dean for research development; Cecilia Haas, M.S., CFM, assistant director of facilities planning; and John Harb, M.S.P.H., assistant dean for scientific operations and director of the Office of Biotechnology.
The Gottesman Institute for Stem Cell and Regenerative Medicine Research is supported by external sources, including the NIH and the New York State Stem Cell Research Program, as well as by a major generous gift from the Gottesman family.
Currently, Einstein has a faculty base of nearly two dozen NIH-funded stem cell investigators tackling some of the world's most challenging diseases – including liver failure, cancer and heart disease. Einstein has been a leading recipient of stem cell funding from New York State since its 2008 initiative to commit $600 million in the next decade to advance stem cell science in the state (NYSTEM). To date, Einstein researchers have received over $15 million in NYSTEM funding, including two new awards totaling over $1.4 million announced last month.
The recent NYSTEM grants were awarded to Jayanta Roy-Chowdhury, M.B.B.S., professor of medicine and of genetics, and Ulrich Steidl, M.D., Ph.D., the Diane and Arthur B. Belfer Faculty Scholar in Cancer Research and assistant professor of cell biology. Dr. Roy-Chowdhury was awarded a $1,080,000 Investigator-Initiated Research Project grant to study the Amelioration of Hepatic Metabolic Defects by Stem Cell-Derived Human Hepatocytes. Dr. Steidl was awarded $330,000 for an Innovative, Developmental or Exploratory Activities award for Identifying Epigenomic Determinants of Hematopoietic Stem Cell Commitment.
###
About Albert Einstein College of Medicine of Yeshiva University
Albert Einstein College of Medicine of Yeshiva University is one of the nation's premier centers for research, medical education and clinical investigation. During the 2009-2010 academic year, Einstein is home to 2,775 faculty members, 722 M.D. students, 243 Ph.D. students, 128 students in the combined M.D./Ph.D. program, and approximately 350 postdoctoral research fellows. In 2009, Einstein received more than $155 million in support from the NIH. This includes the funding of major research centers at Einstein in diabetes, cancer, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Through its extensive affiliation network involving five medical centers in the Bronx, Manhattan and Long Island – which includes Montefiore Medical Center, The University Hospital and Academic Medical Center for Einstein – the College of Medicine runs one of the largest post-graduate medical training programs in the United States, offering approximately 150 residency programs to more than 2,500 physicians in training. For more information, please visit www.einstein.yu.edu
--------------------------------------------------------------------------------
[ Print | E-mail | Share ] [ Close Window ]
press release
April 15, 2010, 3:57 p.m. EDT · Recommend · Post:
Stemgent and Pfizer Announce Collaboration
Research and Licensing Agreement Allows Stemgent to Offer Research Compounds from Pfizer
BOSTON & NEW YORK, Apr 15, 2010 (BUSINESS WIRE) -- --Dr. Ruth McKernan, CSO of Pfizer Regenerative Medicine, to Join Stemgent's SAB
Stemgent, Inc. and Pfizer Inc. /quotes/comstock/13*!pfe/quotes/nls/pfe (PFE 16.99, -0.07, -0.41%) today announced a collaboration and research licensing agreement that will lead to certain research reagents developed or discovered by Pfizer being made available to the global research community through Stemgent. Stemgent provides research tools and services to institutions, companies and universities in advancing in vitro and in vivo non-human stem cell research.
According to the agreement, scientists involved in cell-based research will now be able to purchase fully licensed compounds with pharmaceutical modes of action as off-the-shelf products for use in non-clinical experiments. It is hoped that along with other Stemgent offerings, the materials will greatly benefit scientists working in a diverse range of stem cell and cell-based applications, including neuroscience, cancer and metabolic disease.
As part of the agreement, Pfizer and Stemgent will form a joint research committee to review and evaluate the collaboration's progress, coordinate results publication, monitor information and materials exchange between the two parties, nominate compounds and provide guidance relating to research tools for use in stem cell research.
"We are pleased to form this partnership with Stemgent," said Ruth McKernan, Ph.D., chief scientific officer of Pfizer Regenerative Medicine. Dr. McKernan will also join Stemgent's scientific advisory board. "We applaud the efforts Stemgent has made in bringing important research tools to the stem cell community. We all need research tools such as the molecules Stemgent can offer to dissect the pathways involved in stem cell biology and to advance our understanding of the science. I am delighted to join other industry and academic leaders on Stemgent's Scientific Advisory Board."
Commenting on the collaboration, Ian Ratcliffe, President and Chief Executive Officer of Stemgent, said, "This is an important step for the scientific community as it increases our potential small molecule product offerings at a time when stem cell research gathers momentum and size around the world. We are especially pleased to have Dr. McKernan on our SAB; her experience and intellect bring tremendous value to our already globally respected group of scientific advisors."
About Pfizer Inc: Working together for a healthier world(TM)
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.
About Stemgent
Stemgent advances stem cell science by providing proprietary reagents and tools developed by some of the world's leading stem cell scientists. Stemgent's product offering has been specifically optimized for and screened against stem cells, and includes small molecules for pluripotency, self-renewal, and differentiation, viral-delivered transcription factors, matrices, cell lines, cytokines, antibodies, transfection reagents, and more. This unique product mix is designed to serve researchers who study stem cell biology and regenerative medicine, and those who use cells derived from stem cells as tools to advance their understanding of major diseases. With dual science facilities in Boston, Massachusetts, and San Diego, California, Stemgent is well positioned to serve these major research markets. For more information on Stemgent, please visit: http://www.stemgent.com.
PFIZER DISCLOSURE NOTICE: The information contained in this release is as of April 15, 2010. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about the potential benefits of a collaboration and research licensing agreement entered into by Pfizer and Stemgent that involves substantial risks and uncertainties. A description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6251885&lang=en
SOURCE: Pfizer Inc.
Pfizer
Samantha Cummis, 212-733-6924
Samantha.cummis@pfizer.com
or
Stemgent
Lloyd Dahmen, 617-245-0018
Lloyd.Dahmen@stemgent.com
or
Media
The Communications Strategy Group
Edward D. Agne, 781-631-3117
edagne@comstratgroup.com
Copyright Business Wire 2010
3 States in 3 Weeks: Virginia, Ohio and Tennessee Legislate Cord Blood Education
http://blog.cordblood.com/archive/2010/04.aspx?fbid=9_qksOkAlDV
Posted: Apr 06, 2010
In a recent post, we reported that Virginia passed the Cord Blood Education Bill. Just three short weeks later, two additional states – Ohio and Tennessee – have passed very similar legislation.
The growing number of states to enact cord blood education legislation stems from the Institute of Medicine’s (IOM) 2004 report to Congress. That report highlighted the need to help all expectant parents make an informed choice prior to labor and delivery about the storage or disposal of their newborn’s cord blood stem cells.
The hope is that these new laws will do just that, specifically by:
• Encouraging prenatal care providers to educate expectant parents about their cord blood banking options early enough in pregnancy so that they can make an informed decision about whether to privately bank their child’s newborn stem cells or donate them to a public bank.
• Requiring the state’s Department of Health to publish information on its website about cord blood stem cells and parents’ options for preserving them.
Now a total of 20 states – representing 68% of the U.S. population – have legislation in place endorsing education on cord blood stem cells and the private and public cord blood banking options available to parents.
This was posted by MrLong on CBAI board.
Bioheart Commenced Successful Regenerative Stem Cell Treatments with Latin American Patients Having Congestive Heart Failure
Date : 04/14/2010 @ 4:05PM
Source : PR Newswire
Stock : Bioheart (BB) (BHRT)
Quote : 0.75 0.05 (7.14%) @ 10:20AM
Bioheart Commenced Successful Regenerative Stem Cell Treatments with Latin American Patients Having Congestive Heart Failure
Bioheart Commenced Successful Regenerative Stem Cell Treatments with Latin American Patients Having Congestive Heart Failure
PR Newswire
SUNRISE, Fla., April 14
SUNRISE, Fla., April 14 /PRNewswire-FirstCall/ --
Bioheart, Inc. (OTC Bulletin Board: BHRT) announced that treatment with stem cell therapy on two congestive heart failure (CHF) patients was performed successfully at the Hospital Angeles Tijuana, Mexico, through Bioheart's Center of Excellence program with Regenerative Medicine Institute.
The therapy employed stem cells derived from the patient's own fat (adipose tissue) obtained using liposuction. Stem cells were separated from the adipose tissue utilizing the fully-automated TGI 1200 Cell Isolation System. The separation process takes about an hour. No tissue pre-processing is required with this system. The recovered stem cells were injected into the patients' hearts utilizing Bioheart's MyoCath® needle injection catheter.
Dr. Karl Groth, Bioheart's Chairman and Chief Executive Officer explained, "These procedures validate Bioheart's innovation of effective treatments for the most serious cardiac health issues confronting people around the world. Our mandate is to bring Bioheart's solutions wherever they are needed and can be utilized."
These first two Latin American patients and other patients treated in Tijuana with Bioheart's cell therapies through Regenerative Medicine Institute will be followed at intervals of three and six months, and then a year, to assess their progress. The principal endpoint will be improvement in the six minute walk distance, a key measure for cardiac well being. Also measured will be improvement in the heart's viability, strength, and ability to function. The key to reversing the impact of heart disease is reduction in scar tissue. The therapy encourages the regeneration of heart muscle tissue, allowing new vibrant tissue to grow and enabling the pumping of blood by the heart to improve. The new tissue integrates into the scarred areas that are inactive, causing activity. Stem cells and myoblasts, which are muscle stem cells, are the bases for Bioheart's therapies.
In March, Bioheart entered into the first of its five planned agreements in Latin America to establish Centers of Excellence for the introduction of its therapies. The Regenerative Medicine Institute of Tijuana, Mexico is the first of these programs and provides therapies for congestive heart failure and peripheral arterial disease (PAD) patients at the Hospital Angeles Tijuana, a fully equipped state-of–the-art private specialties hospital.
Dr. Warren Sherman of Columbia University Medical Center's Stem Cell Research Institute was present at the procedures and assisted with the technology transfer. He, along with Dr. Christopher O'Conner, and Dr. Thomas Povsic, MD, PhD, of Duke University's Clinical Research Institute, have, with Bioheart, established an Academic Advisory Committee to monitor Bioheart's Centers of Excellence and gather data on the results seen by each Center. These results will, over time, become a compendium and form a nexus for future cell therapy research.
About Bioheart's program enabling treatment to be conducted in Centers outside the US, Dr. Sherman says, "I have come to believe that valuable knowledge can be gained from small-to-moderate sized clinical studies conducted outside of the US. Depending on objectives and design, the costs and logistics of certain studies can be burdensome, or even prohibitive to conduct in the US. The two key points here are, first and foremost, to ensure the rights and safety of patients, wherever a clinical trial is done. And secondly, that data arising from the study be complete and transparent. Without both elements in-place, a study will unlikely add to our knowledge of stem cell repair, or advance the field. To my eyes, Bioheart's initiative ensures that the integrity of both treatment and data collection is preserved, and I anticipate the scientific community will eagerly follow the program's progress."
Recent studies have identified adipose tissue as an alternate source of stem cells. The procedure for obtaining adipose derived stem cells from the patient is a relatively simple process and tolerated by most patients even immediately following a heart attack. Fat tissue can usually be found in abundance within the patient's own body and has a greater number of stem cells than bone marrow. The TGI 1200 Cell Isolation System can isolate stem cells in about an hour, allowing for immediate clinical, point-of-care treatment after an event like a heart attack, which is important to the effectiveness of the treatment. In contrast, the procedure for obtaining stem cells from bone marrow can be painful and often yields a low volume of stem cells.
Anton Krucky, CEO of Tissue Genesis, commented on Bioheart's successes with the use of the TGI system: "We are excited about the momentum that Bioheart is gaining in the use of Tissue Genesis' methods and technologies. Their recent successes in Europe and South America give us a great deal of confidence in Bioheart's ability to deliver cardiovascular regenerative medicine services to the Americas."
In addition to offering treatment for congestive heart failure with the TGI system, the Regenerative Medicine Institute will be using the system to treat lower limb ischemia using a similar process. The TGI 1200 Cell Isolation System is currently being utilized in clinical studies to treat chronic heart ischemia in Venezuela and critical limb ischemia in the Czech Republic.
Dr. Javier Lopez, Regenerative Medicine Institute's President, stated: "It is valuable to be able to help those in our country who are suffering from congestive heart failure and other cardiovascular problems that can be resolved with Bioheart's therapies and enables our Institute to be in the forefront of treatment centers around the world."
The final step for incorporating Bioheart therapies into its program will be adding MyoCell®, Bioheart's muscle stem cell therapy for CHF. MyoCell® is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.
About the TGI 1200 Cell Isolation System
The CE-marked TGI 1200 Cell Isolation System is a fully automated and simple system, which processes liposuctioned fat tissue and delivers isolated regenerative cells in about an hour. The compact desktop unit requires no tissue pre-processing, and fits easily into any clinical environment. The instrument allows for point-of-care recovery of an average of 50 million regenerative cells per 60cc of a patient's processed fat. These cells can then be used at the site of injury or disease. Regenerative cells may amplify the body's own repair process, accelerate healing, repair damaged and diseased tissue, and prevent scarring and loss of function.
About Heart Failure
Heart failure is a debilitating condition. When heart failure is in an advanced state, the heart is unable to pump enough blood to the body to allow a person to enjoy a normal, productive life. This disease affects over 5 million people in the United States. Over 500,000 new cases are diagnosed annually in the U.S., making heart failure the most rapidly growing of all cardiovascular disorders. According to statistics provided by the American Heart Association, the approximate direct and indirect annual cost of heart failure treatment in the U.S. is $22.5 billion. Persons over the age of 65 experience heart failure as the number one cause of hospitalization and the number one cause of death.
About Bioheart, Inc
Bioheart is committed to maintaining a leading position within the cardiovascular sector of the cell technology industry delivering cell therapies, intelligent devices and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. The Company works to prevent the worsening of any condition employing devices that monitor and diagnose. Bioheart's expertise is regenerating damaged tissue, if possible, and improving a patient's quality of life in addition to reducing health care costs and hospitalizations.
Specific to biotechnology, the Company is focused on the discovery, development and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease, subject to regulatory approval. MyoCell, the Company's principal therapy, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.
For more information on Bioheart, visit www.bioheartinc.com.
Forward-Looking Statements:
Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our ability to obtain additional financing; (ii) our ability to control and reduce our expenses; (iii) our ability to establish a distribution network for and commence distribution of certain products for which we have acquired distribution rights; (iv) our ability to timely and successfully complete our clinical trials; (v) the occurrence of any unacceptable side effects during or after preclinical and clinical testing of our product candidates; (vi) the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; (vii) our dependence on the success of our lead product candidate; (viii) our inability to predict the extent of our future losses or if or when we will become profitable; (ix) our ability to protect our intellectual property rights; and (x) intense competition. The Company is also subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2009.
Contact:
At the Company:
Karl E. Groth, Ph.D., Chairman and Chief Executive Officer
kgroth@bioheartinc.com
(954) 835-1500
SOURCE Bioheart, Inc.
Interesting article locks... but, here's the thing I don't understand. Or, one of them. ;)
Take this line from the article:
International Stem Cell Corporation Provides Strategic Update on Its Skin Care Program
Date : 04/08/2010 @ 7:30AM
Source : Business Wire
Stock : International Stem Cell Corporation (ISCO)
Quote : 2.07 0.0 (0.00%) @ 8:08AM
International Stem Cell Corporation Provides Strategic Update on Its Skin Care Program
International Stem Cell Corporation (OTCBB: ISCO), www.internationalstemcell.com, announces today that its wholly owned subsidiary, Lifeline Skin Care Inc., has achieved positive results in human safety tests of its cosmetic products and is moving forward with arrangements with Cosmetic Enterprises Ltd. for the manufacture of three cosmetic products. These developments allow Lifeline Skin Care to plan a launch of its cosmetic product line in the late summer or fall of 2010.
Cosmetic face products developed by Lifeline Skin Care Inc. contain extracts from human parthenogenetic stem cells (hpSC) combined with a vitamin complex and other active ingredients. The products utilize a form of nanotechnology to deliver concentrated active ingredients to damaged skin. Laboratory tests show that an active “complex” of stem cell extract has the ability to rejuvenate skin. Also, early human trials show that these cosmetic products moisturize skin and strongly indicate the ability to decrease the depth of wrinkles and provide factors that lead to anti-aging effects.
Lifeline Skin Care is working with Cosmetic Enterprises, Ltd., located in California, to formulate and package its unique skin care product. Cosmetic Enterprises is a well-known OTC drug licensed manufacturer with over 30 years of experience. Lifeline Skin Care’s “parthenogenetic stem cell complex” the product’s active ingredient, is made in Lifeline Skin Care’s laboratory in Oceanside, California.
According to Gregory S. Keller, MD, FACS, “These positive safety studies in human testing are important, especially considering that preliminary human trial data show that products of the production of International Stem Cell’s parthenogenetic stem cells have significant beneficial effects on the skin and might also provide long term benefits in reducing wrinkles and other visible signs of aging. These results are a significant step forward in making this unique product available to the public.” Dr. Keller was named the 2007 “Specialist of the Year in Facial Cosmetic Surgery” in Strathmore’s “Who’s Who”.
The results of recent human safety tests show there were no identifiable signs or symptoms of sensitization (contact allergy). Safety testing is a series of tests to insure the product does not cause negative reactions such as irritation to the skin. This completed round of testing allows Lifeline Skin Care to move forward confidently with its commercial manufacturing plans.
International Stem Cell Corporation is a pioneer in development of a new class of stem cells called “human parthenogenetic stem cells” which avoid critical ethical issues by eliminating the need to use fertilized embryos and can be immune-matched to large segments of the population. As of today, ISCO has successfully derived 10 hpSC lines. One of these lines (hpSC-Hhom-4), carries the most common immune type found across racial groups within the US population and can be immune-matched to millions of people.
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):
International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO’s core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology. More information is available at ISCO’s website, www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
FORWARD-LOOKING STATEMENTS
Statements pertaining to anticipated technological developments and therapeutic applications, and other opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "should," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.
Key Words: Skin Care, Stem Cells, Biotechnology, Parthenogenesis
The things that slow down the Research News:
The stem cell banking crisisPosted by Jef Akst
[Entry posted at 7th April 2010 09:00 PM GMT]
The National Institutes of Health (NIH) has allowed a contract for the dissemination of embryonic stem cell lines approved for US government funding to lapse, shuttering a key stem cell bank, and doubling the price researchers pay for samples of some human embryonic stem cell (hESC) lines.
Human embryonic stem cells
Nissim Benvenisty
Researchers hoped that stem cell research would be moving forward by leaps and bounds with the number of hESC lines approved for federal funding more than doubling since the limitations of the Bush administration were lifted in 2009. But a major stumbling block remains -- getting those newly approved lines to the researchers who want to use them.
In 2005, the National Stem Cell Bank (NSCB) was established at the WiCell Institute in Wisconsin to distribute the 21 Bush administration-sanctioned lines to labs around the country. But last month, the NIH let the NSCB contract expire, forcing the bank to shut down. Though the lines are now available through the Wisconsin International Stem Cell (WISC) Bank, the lack of government subsidization has caused the prices to double from $500 per vial of frozen cells to $1000.
"We now suddenly have to be a break even," said Erik Forsberg, executive director of WiCell. "We have a pretty good handle on costs and revenue, [but] we'll just have to see how it goes," he said, commenting that if the bank's sales go down, it may be forced to raise its prices even more.
Furthermore, only one of those 21 lines approved under the Bush administration and distributed by the WISC Bank are eligible for federal funding under the new NIH guidelines. All of the other 50 newly approved lines are scattered among a handful of institutions, none of which have a distribution center set up to handle the administrative burdens of taking, filling, shipping, and tracking orders.
Harvard Stem Cell Institute researcher George Daley, whose lab generated 11 of the hESC lines approved in the new NIH registry, is doing what he can to distribute those lines from his Children's Hospital Boston lab "in the short term," he said in an email to The Scientist, but "we're not in the business of 'selling' the lines." Daley said that they are currently shipping the lines to at least 3 dozen groups, but at $500 per order and no supporting funding, "we are [taking] an overall loss," he said. "The field definitely needs some bank or banks to step up."
The distribution of federally funded hESC lines is "probably best achieved" through large organizations such as the Coriell Institute for Medical Research in New Jersey, the University of Massachusetts Stem Cell bank, or the American Type Culture Collection (ATCC), Daley added. This past January, the NIH expanded its contract with the Coriell Institute to include the banking of induced pluripotent stem (iPS) cell lines, providing the bank with a five-year, $27 million contract for a human genetic biobank and new stem cell laboratory. No plans have been made, however, regarding embryonic stem cell line banking.
The ATCC also does "not anticipate acquiring [the newly-approved hESC lines] at this time," said ATCC spokesperson Nancy Wysocki, noting that "this does not exclude the possibility that we might distribute them for others at a future date."
The NIH may take matters into its own hands, establishing its own cell bank to distribute the new lines to researchers. "NIH is seriously considering various options, including banking, to ensure that NIH grantees have access to human embryonic stem cell lines that derivers are willing to share with the research community," said an agency spokesperson.
"Depositing the cell lines in publically supported banks only makes sense," agreed James Thomson, stem cell researcher and one of the founders of the NSCB. But one bank may not be enough, he added. "I think it is important that NIH support multiple such banks for both human ES and iPS cell lines [so] there could be regional support and competition, and the over-all quality would continue to improve."
Meanwhile, researchers continue calling for the addition of the other 20 Bush-approved lines to the NIH registry -- a task that the WISC Bank is working on, Forsberg said.
Related stories:
Stem cell banks galore
[25th September 2008]
UK stem cell bank to begin distribution
[19th September 2006]
UK stem cell bank ready to go
[18th September 2003]
For FREE access to this news story and more, you must register.
The article you are attempting to read is only available to registered users of The Scientist. Registration is FREE and only takes a few seconds.
Email
Password
> Forgot Password?
> FAQ
> Subscribe
Create your MyScientist account and access all of The Scientist's free content, tools and life science email newsletters, including:
> The current month’s print issue
> Daily & Bi-weekly e-mail newsletters
> Newsblogs with breaking headlines
> The Scientist Community
> Exclusive web extras
> The Scientist Careers
Premium content from The Scientist Archive, a comprehensive resource of over 22 years of past life science coverage, is available only by subscription. Subscribe today and get unlimited access
LATEST NEWS
The stem cell banking crisis
--------------------------------------------------------------------------------
Announcing The Scientist's Labbies
--------------------------------------------------------------------------------
Gut bacteria are what we eat
--------------------------------------------------------------------------------
Wildlife manager or exterminator?
--------------------------------------------------------------------------------
News in a nutshell
--------------------------------------------------------------------------------
Father of liposomes dies
--------------------------------------------------------------------------------
Beyond the field trip crowd
--------------------------------------------------------------------------------
Plagiarism retracts review
--------------------------------------------------------------------------------
Bird genes help explain speech
--------------------------------------------------------------------------------
Key cancer patents killed
--------------------------------------------------------------------------------
News in a nutshell
--------------------------------------------------------------------------------
Q&A: Translation deCODEd
--------------------------------------------------------------------------------
Creature cast
--------------------------------------------------------------------------------
NIH boosts its clinical core
--------------------------------------------------------------------------------
New clue to how telomeres work
--------------------------------------------------------------------------------
More Entries...
Read more: The stem cell banking crisis - The Scientist - Magazine of the Life Sciences http://www.the-scientist.com/blog/display/57274/#ixzz0kUkBhsBj
This board is primarily for companies into cord blood storage since control of inventory will control treatments in the future. Discussion of updates in the field of stem cells and regenerative medicine will also be found.
Stem Cells – An overview
http://www.youtube.com/user/rorygirl#p/c/C9DB8E6493B73432/8/mUcE1Y_bOQE
Regenerative Medicine: Re-Growing Body Parts
http://www.youtube.com/user/rorygirl#p/c/C9DB8E6493B73432/16/GwcT1ViM-hw
Regenerative Medicine: Pathways to Cure - Version 2.0
http://www.youtube.com/user/rorygirl#p/c/C9DB8E6493B73432/15/tQ41GrOIbkE
The Stem Cell Stock Index
http://www.stemdex.com/2009/07/stem-cell-stock-index.html
The Stem Cell Tracker
http://www.stemcelltracker.com/
Diseases NOW Being Treated by Repair Stem Cells
http://repairstemcells.org/Treatment/Diseases-Treated.aspx
Global Cord Blood Stem Cells Market to Hit US$15 billion by 2015
http://www.prlog.org/10453315-global-cord-blood-stem-cells-market-to-hit-us15-billion-by-2015.html
Following are just a few of the companies in this arena. Listings are in alphabetical order by ticker:
ACTC - http://investorshub.advfn.com/boards/board.aspx?board_id=5319
http://www.advancedcell.com/
--------------------
AMST, formerly SCII - http://investorshub.advfn.com/boards/board.aspx?board_id=120
http://amsteminc.com/
--------------------
BCLI – http://investorshub.advfn.com/boards/board.aspx?board_id=4829
http://www.brainstorm-cell.com/
--------------------
CBAI - http://investorshub.advfn.com/boards/board.aspx?board_id=3650
Websites:
http://www.cordblood-america.com
http://www.cordpartners.com
http://www.cord-blood-video.com
http://www.curesource.net
http://www.corcell.com
--------------------
CCEL - http://investorshub.advfn.com/boards/board.aspx?board_id=3965
http://www.cryo-cell.com
Cryo-Cell Mexico offers services in Mexico, Central America and Ecuador.
Asia Cryo-Cell Private Limited offers services in India.
C'elle distributor opportunity for doctors that specialize in female issues. See video:
http://www.celle.com/distributorVideo.aspx#
--------------------
CO - http://investorshub.advfn.com/boards/board.aspx?board_id=16014
http://www.chinacordbloodcorp.com
--------------------
ISCO - http://investorshub.advfn.com/boards/board.aspx?board_id=13281
http://www.internationalstemcell.com/index.html
--------------------
SSS.V - http://investorshub.advfn.com/boards/board.aspx?board_id=11538
--------------------
Last update 4.20.2010
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Rules of the board
Respect each other
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |